<DOC>
	<DOCNO>NCT00783133</DOCNO>
	<brief_summary>This crossover study design see patient seasonal allergy symptom prefer Clarinex速 Allegra速 . Patients randomize take 7 day Clarinex Allegra treatment , follow 5 28-day washout period ( day drug give ) , follow 7 day opposite treatment . At end 7-day treatment , patient ask question determine drug , Clarinex Allegra , patient prefers .</brief_summary>
	<brief_title>Preference Clarinex Tablets vs. Allegra Tablets Patients With Seasonal Allergies ( Study P03177 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>least twoyear history seasonal allergic rhinitis ; currently experience symptom SAR , include nasal symptom Visits 2 4 , prior enter treatment phase ; take Allegra速 Clarinex速 within previous year ; 18 year age older ; negative urine test ( hCG ) females childbearing potential ; woman childbearing potential , agree use medically accept method birth control ; free clinically significant disease ( SAR ) would interfere study evaluation ; pregnant nursing ; allergic idiosyncratic reaction antihistamine ; current history frequent , clinically significant sinusitis chronic purulent nasal discharge ; rhinitis medicamentosa nasal structural abnormality ( include large nasal polyp mark septal deviation ) significantly interfere nasal airflow ; opinion Investigator , dependent upon nasal , oral ocular decongestant , nasal topical antihistamine , nasal steroid ( ie. , subject could would observe washout period prohibit medication ) ; upper respiratory tract sinus infection require antibiotic therapy last dose within 14 day prior Screening , viral upper respiratory infection within 7 day prior Screening ; asthma , unless symptom could control shortacting inhaled Beta2agonist use `` need '' basis ; immunotherapy , unless stable maintenance schedule prior screen . The dose immunotherapy remain constant subject could receive immunotherapy within 24 hour prior visit ; history psychosis , antagonistic personality , poor motivation , hypochondriasis , emotional intellectual problem likely limit validity consent participate study ; history noncompliance medication treatment protocol ; clinically significant deviation normal physical examination , Investigator 's judgment , may interfere study evaluation affect subject safety ; clinically significant metabolic , cardiovascular , immunologic , neurologic , hematologic , gastrointestinal , cerebrovascular , respiratory disease , disorder , judgment Investigator , might interfere study evaluation affect subject safety ; liver renal impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>